UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

 WASHINGTON, D.C. 20549

 FORM 10-K/A

 (Amendment No. 1)

 (Mark One)

 ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the fiscal year ended June 30, 2023

 OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the transition period from to

 Commission file number: 001-39685

 INMED PHARMACEUTICALS INC.

 (Exact name of registrant as specified in its charter)

 British Columbia, Canada

 98-1428279

 (State or other jurisdiction of

incorporation or organization)

 (IRS employer

Identification number)

 Suite 310 – 815 W Hastings, Vancouver, B.C.,
 Canada

 V6C 1B4

 (Address of principal executive office)

 (Zip Code)

 (604) 669-7207

 (Registrant's telephone number, including area code)

 Securities registered pursuant to Section 12(b) of the Exchange
Act:

 Title of Each Class

 Trading Symbol

 Name of Each Exchange On

Which Registered

 Common Stock, no par value

 INM

 The Nasdaq Capital Market

 Securities registered pursuant to Section 12(g) of the Act:
None

by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes
 No

by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes No

by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
 Yes No

 Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company.
See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company,"
and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 Large accelerated filer

 Accelerated filer

 Non-accelerated filer

 Smaller reporting company

 Emerging growth company

 I f
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

by check mark whether the registrant has fi led a report on and attestation to its management's assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting fi rm that prepared or issued its audit report.

 If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements.

by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 As
of December 31, 2022, the last business day of the Registrant's most recently completed second fiscal quarter, the aggregate market
value of the Company's voting and non-voting common equity held by non-affiliates of the Registrant was $ 3,180,248.

 On
September 29, 2023, there were 3,328,191 shares of the registrant's comm on stock outstanding.

 DOCUMENTS INCORPORATED BY REFERENCE

 None.

 Auditor Name:

 Auditor Location:

 Auditor Firm ID:

 Marcum LLP

 New York, NY

 EXPLANATORY NOTE

 We are filing
this Amendment No. 1 to our Annual Report on Form 10-K solely for the purpose of updating our auditor's consent in Exhibit 23.1
to include our Registration Statement on Form S-8 (File No. 333-268356).

 Outside of the change to the exhibit noted above
and the updated certifications of the Chief Executive Officer and Chief Financial Officer, this Form 10-K/A does not otherwise amend,
supplement, update or revise any portion of the original Form 10-K which remains unchanged since the date of its filing. Furthermore,
this Form 10-K/A does not change any previously reported financial results, nor does it reflect events occurring after the date of the
original Form 10-K. Information not affected by this Form 10-K/A remains unchanged and reflects the disclosures made at the time the original
Form 10-K was filed.

 i

 ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 The following documents are being filed
as part of this report:

 (1)

 Financial Statements

 The financial statements required by this item were submitted
 with the Original Form 10-K. Refer to Part II, Item 8, " Financial Statements and Supplementary Data " of the Original
 Form 10-K.

 (2)

 Financial statement schedules have been omitted because of the absence of conditions under which they are required or because the required information is included in the financial statements or notes thereto submitted as part of the Original Form 10-K.

 (3)

 A list of exhibits filed with this report is found below.

 EXHIBIT

 NUMBER

 DESCRIPTION

 23.1

 Consent of Marcum LLP.

 31.1

 Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 31.2

 Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 32.1

 Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 32.2

 Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 101.INS*

 101.SCH*

 101.CAL*

 101.DEF*

 101.LAB*

 101.PRE*

 104*

 *
 Previously filed.

 ITEM 16. 10-K SUMMARY

 Not applicable.

 SIGNATURES

 Pursuant to the requirements of Section
13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

 INMED PHARMACEUTICALS INC.

 (Registrant)

 By:

 /s/ Jonathan Tegge

 Jonathan Tegge

 Interim Chief Financial Officer

and Principal Accounting Officer

 Pursuant to the requirements of the Securities
and Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities
and on the dates indicated.

 Signature

 Title

 Date

 /s/ Eric A. Adams

 President, Chief Executive Officer and Director

 Eric A. Adams

 (Principal Executive Officer)

 /s/ Jonathan Tegge

 Interim Chief Financial Officer

 Jonathan Tegge

 (Principal Financial Officer and Principal Accounting Officer)

 /s/ Andrew Hull

 Director (Chairman to the Board of Directors)

 Andrew Hull

 /s/ Janet Grove

 Director

 Janet Grove

 /s/ Bryan Baldasare

 Director

 Bryan Baldasare

 /s/ Nicole Lemerond

 Director

 Nicole Lemerond

 true FY 0001728328

 0001728328

 2022-07-01
 2023-06-30

 0001728328

 2022-12-31

 0001728328

 2023-09-29